← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Zhongchao Inc. (ZCMD) 10-Year Financial Performance & Capital Metrics

ZCMD • • Industrial / General
HealthcareHealthcare ITHealthcare Data Analytics & AIHealthcare Business Intelligence
AboutZhongchao Inc. provides healthcare information, education, and training services in the People's Republic of China. The company offers online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes of popular medical topics, interactive case studies, academic conference and workshops, continuing education courses, and articles and short videos with educational healthcare content. It also provides customized medical courses and medical training services; and patient management services through online platform under the Zhongxun brand. The company operates through its mdmooc.org online platform under the MDMOOC brand; and Sunshine Health Forums, a Wechat subscription account and mobile app. It serves enterprises, non-for-profit organizations, and medical journals, as well as healthcare professionals, nurses, doctors, and other healthcare workers. The company was founded in 2012 and is headquartered in Shanghai, China.Show more
  • Revenue $16M -18.4%
  • EBITDA $87K +100.7%
  • Net Income -$643K +94.3%
  • EPS (Diluted) -0.12 +97.2%
  • Gross Margin 56.18% +28.3%
  • EBITDA Margin 0.55% +100.9%
  • Operating Margin -2.15% +96.9%
  • Net Margin -4.05% +93.0%
  • ROE -2.85% +93.2%
  • ROIC -1.67% +96.9%
  • Debt/Equity 0.00 -93.8%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Trading at only 0.1x book value

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Weak momentum: RS Rating 7 (bottom 7%)
  • ✗Shares diluted 100.0% in last year
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y1.29%
3Y-0.89%
TTM-5.23%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM2.4%

EPS CAGR

10Y-
5Y-
3Y-
TTM16.91%

ROCE

10Y Avg5.62%
5Y Avg-7.91%
3Y Avg-19.19%
Latest-1.48%

Peer Comparison

Healthcare Business Intelligence
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
NRCNational Research Corporation482.6M21.3020.48-3.72%11.76%114.31%3.97%2.06
WORXSCWorx Corp.2.91M0.18-0.24-21.43%-139.71%-64.87%0.01
DHDefinitive Healthcare Corp.251.03M2.43-0.690.31%-77.88%-48.42%18.27%0.42
HCATHealth Catalyst, Inc.165.51M2.34-2.033.6%-34.05%-32.42%1.10
ZCMDZhongchao Inc.12.21M0.47-3.95-18.37%-26.94%-34.62%0.00
EVHEvolent Health, Inc.439.71M3.94-4.8630.09%-6.24%-15.22%0.71
FORAForian Inc.66.18M2.13-17.75-1.6%-3.03%-2.74%0.43%0.22

Profit & Loss

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+9.82M12.87M14.88M17.99M16.3M14.15M19.43M15.86M
Revenue Growth %-0.31%0.16%0.21%-0.09%-0.13%0.37%-0.18%
Cost of Goods Sold+3.97M4.46M4.66M6.12M6.86M7.79M10.92M6.95M
COGS % of Revenue0.4%0.35%0.31%0.34%0.42%0.55%0.56%0.44%
Gross Profit+5.85M8.41M10.23M11.87M9.44M6.36M8.51M8.91M
Gross Margin %0.6%0.65%0.69%0.66%0.58%0.45%0.44%0.56%
Gross Profit Growth %-0.44%0.22%0.16%-0.2%-0.33%0.34%0.05%
Operating Expenses+4.8M5.13M6.58M7.38M9.76M9.31M21.8M9.25M
OpEx % of Revenue0.49%0.4%0.44%0.41%0.6%0.66%1.12%0.58%
Selling, General & Admin3.85M3.69M5.72M6.57M9M8.9M13.41M9M
SG&A % of Revenue0.39%0.29%0.38%0.36%0.55%0.63%0.69%0.57%
Research & Development943.25K1.45M864.32K816.55K758.88K411.52K514.41K252.45K
R&D % of Revenue0.1%0.11%0.06%0.05%0.05%0.03%0.03%0.02%
Other Operating Expenses037.36K00007.87M863
Operating Income+1.05M3.27M3.64M4.49M-320.74K-2.95M-13.28M-341.27K
Operating Margin %0.11%0.25%0.24%0.25%-0.02%-0.21%-0.68%-0.02%
Operating Income Growth %-2.12%0.11%0.23%-1.07%-8.21%-3.5%0.97%
EBITDA+1.06M3.3M3.88M4.67M-2.32K-2.22M-12.36M87.09K
EBITDA Margin %0.11%0.26%0.26%0.26%-0%-0.16%-0.64%0.01%
EBITDA Growth %-2.1%0.18%0.2%-1%-958.51%-4.56%1.01%
D&A (Non-Cash Add-back)16.27K28.78K240.51K180.66K318.42K730.31K923.61K428.36K
EBIT1.34M3.27M4.39M4.49M-320.74K-2.95M-5.41M-340.4K
Net Interest Income+17.33K191.61K211.48K146.97K175.99K142.01K237.05K243.01K
Interest Income17.33K191.61K211.48K146.97K175.99K142.01K237.05K243.01K
Interest Expense00000000
Other Income/Expense292.35K228.97K745.5K452.53K209.99K404.46K1.31M403.02K
Pretax Income+1.34M3.5M4.39M4.94M-110.75K-2.55M-11.98M61.76K
Pretax Margin %0.14%0.27%0.29%0.27%-0.01%-0.18%-0.62%0%
Income Tax+-153.95K502.13K387.14K484.79K-349.42K272.31K-669.76K335.17K
Effective Tax Rate %1.14%0.86%0.92%0.9%-2.15%1.15%0.95%-10.42%
Net Income+1.53M3.02M4.05M4.46M238.66K-2.94M-11.34M-643.23K
Net Margin %0.16%0.23%0.27%0.25%0.01%-0.21%-0.58%-0.04%
Net Income Growth %-0.97%0.34%0.1%-0.95%-13.32%-2.85%0.94%
Net Income (Continuing)1.49M3M4M4.46M238.66K-2.82M-11.31M-273.41K
Discontinued Operations00000000
Minority Interest-10K-27.84K-46.62K003.09M3.03M3.31M
EPS (Diluted)+0.781.451.871.830.10-1.13-4.35-0.12
EPS Growth %-0.86%0.29%-0.02%-0.95%-12.81%-2.85%0.97%
EPS (Basic)0.781.451.871.830.10-1.13-4.35-0.12
Diluted Shares Outstanding1.96M2.08M2.16M2.44M2.49M2.6M2.6M5.21M
Basic Shares Outstanding1.96M2.08M2.16M2.44M2.49M2.6M2.6M5.21M
Dividend Payout Ratio--------

Balance Sheet

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+6.41M12.56M14.51M29.6M27.25M22.7M18.71M18.71M
Cash & Short-Term Investments4.8M9.08M7.83M17.11M14.21M12.04M13.45M13.08M
Cash Only2.98M7.92M7.83M15.07M13.91M11.52M7.55M7.84M
Short-Term Investments1.82M1.16M02.03M296.16K518.42K5.9M5.24M
Accounts Receivable1.3M1.99M5.17M10.35M12.35M9.13M3.02M4.78M
Days Sales Outstanding48.4156.55126.68210.08276.62235.5856.64109.98
Inventory278.65K1.44M1.49M00189.11K1.98M586.22K
Days Inventory Outstanding25.62117.99117.14--8.8666.1330.78
Other Current Assets64.8K685.67K-826.23K366.97K251.15K70.4K270.08K142.42K
Total Non-Current Assets+566.53K1.48M3.23M5.22M9.01M15.91M5.71M7.18M
Property, Plant & Equipment53.34K669.9K2.14M2.76M4.31M5.8M4.02M5.96M
Fixed Asset Turnover184.05x19.21x6.97x6.51x3.78x2.44x4.84x2.66x
Goodwill000005.77M00
Intangible Assets51.76K436.81K403.73K402.56K383.61K1.22M17.54K12.18K
Long-Term Investments-461.44K-438.42K-1.06M1.26M2.14M1.26M1.31M1.09M
Other Non-Current Assets461.44K438.42K1.06M00000
Total Assets+6.98M14.05M17.74M34.82M36.27M38.61M24.42M25.88M
Asset Turnover1.41x0.92x0.84x0.52x0.45x0.37x0.80x0.61x
Asset Growth %-1.01%0.26%0.96%0.04%0.06%-0.37%0.06%
Total Current Liabilities+1.56M2.33M2.36M2.98M3.59M4.17M2.68M1.53M
Accounts Payable582.13K23.63K117.06K408.43K38.93K140.83K683.94K535.07K
Days Payables Outstanding53.521.949.1824.372.076.5922.8628.09
Short-Term Debt0727.22K210.22K62.16K0480.63K00
Deferred Revenue (Current)712.67K960.65K397.15K6.76K7.43K395.26K838.84K203.79K
Other Current Liabilities149.52K619.35K356.3K759.92K673.54K-385.04K684.67K112.24K
Current Ratio4.10x5.38x6.15x9.92x7.59x5.45x6.99x12.22x
Quick Ratio3.92x4.77x5.52x9.92x7.59x5.41x6.25x11.84x
Cash Conversion Cycle20.5172.6234.64--237.8499.91112.67
Total Non-Current Liabilities+215.18K327.25K41.36K62.16K112.59K1.43M700.11K203.47K
Long-Term Debt00000000
Capital Lease Obligations0041.36K0112.59K1.22M571.86K23.83K
Deferred Tax Liabilities00000208.2K128.25K179.64K
Other Non-Current Liabilities00000000
Total Liabilities1.78M2.66M2.4M2.98M3.7M5.6M3.38M1.73M
Total Debt+0727.22K251.58K62.16K201.56K1.7M808.16K57.52K
Net Debt-2.98M-7.19M-7.58M-15.01M-13.71M-9.82M-6.74M-7.78M
Debt / Equity-0.06x0.02x0.00x0.01x0.05x0.04x0.00x
Debt / EBITDA-0.22x0.06x0.01x---0.66x
Net Debt / EBITDA-2.80x-2.18x-1.95x-3.21x----89.38x
Interest Coverage--------
Total Equity+5.2M11.39M15.34M31.83M32.57M33.02M21.04M24.15M
Equity Growth %-1.19%0.35%1.08%0.02%0.01%-0.36%0.15%
Book Value per Share2.665.487.1013.0313.0612.708.084.64
Total Shareholders' Equity5.21M11.41M15.39M31.83M32.57M29.93M18.01M20.84M
Common Stock2.02K2.16K2.16K2.49K2.5K2.6K2.61K25.39K
Retained Earnings-3.38M-384.31K3.27M7.34M7.18M4.12M-7.27M-7.96M
Treasury Stock00000000
Accumulated OCI208.35K-150.63K71.04K1.72M2.4M803.19K138.27K-287.27K
Minority Interest-10K-27.84K-46.62K003.09M3.03M3.31M

Cash Flow

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-537.65K1.31M1.41M-1.04M2.86M-661.74K54.23K-1.47M
Operating CF Margin %-0.05%0.1%0.09%-0.06%0.18%-0.05%0%-0.09%
Operating CF Growth %-3.44%0.07%-1.74%3.76%-1.23%1.08%-28.17%
Net Income1.49M3M4M4.46M238.66K-2.82M-11.34M-273.41K
Depreciation & Amortization16.27K38.7K262.16K424.68K702.98K730.31K923.61K428.36K
Stock-Based Compensation110.94K-14.48K159.98K168.35K211.82K160.78K135.55K109.71K
Deferred Taxes-153.95K60.98K-318.09K-58.42K-1.35M134.13K-739.23K287.65K
Other Non-Cash Items1.62M1.38M0372.32K1.52M962.49K8.38M-27.24K
Working Capital Changes-2.01M-1.77M-2.7M-6.4M1.53M172.88K2.69M-2M
Change in Receivables-777.42K-792.03K-3.13M-5.49M-104.23K1.08M2.79M-2.32M
Change in Inventory-845.13K-985.77K1.22M-855.7K2.01M-193.83K-409.77K-10.17K
Change in Payables-737.35K-548.51K94.46K260.35K-375.14K103.83K548.59K-132.05K
Cash from Investing+-1.84M-504.05K-203.07K-4.09M-4.02M-3.35M-3.75M-1.81M
Capital Expenditures-81.7K-1.09M-1.31M-848.87K-1.8M-1.86M-839.74K-3.05M
CapEx % of Revenue0.01%0.08%0.09%0.05%0.11%0.13%0.04%0.19%
Acquisitions--------
Investments--------
Other Investing-1.8M-418.52K-14.48K14.49K-3.04M2.03M1.78M277.94K
Cash from Financing+2.73M4.34M-1.19M11.5M01.85M03.84M
Debt Issued (Net)--------
Equity Issued (Net)--------
Dividends Paid00000000
Share Repurchases--------
Other Financing2.73M3.58M-1.19M-388.71K0000
Net Change in Cash--------
Free Cash Flow+-619.35K226.06K95.08K-1.89M1.06M-2.52M-785.51K-4.52M
FCF Margin %-0.06%0.02%0.01%-0.1%0.07%-0.18%-0.04%-0.28%
FCF Growth %-1.36%-0.58%-20.84%1.56%-3.38%0.69%-4.75%
FCF per Share-0.320.110.04-0.770.43-0.97-0.30-0.87
FCF Conversion (FCF/Net Income)-0.35x0.43x0.35x-0.23x11.99x0.23x-0.00x2.29x
Interest Paid05.84K30.31K00000
Taxes Paid-15K144.25K87.11K2.64K91.46K134.23K114.5K45.94K

Key Ratios

Metric20172018201920202021202220232024
Return on Equity (ROE)29.42%36.41%30.29%18.9%0.74%-8.97%-41.94%-2.85%
Return on Invested Capital (ROIC)35.44%76.59%45.71%27.4%-1.35%-10.54%-53.14%-1.67%
Gross Margin59.56%65.36%68.72%65.99%57.92%44.92%43.8%56.18%
Net Margin15.58%23.47%27.19%24.78%1.46%-20.78%-58.33%-4.05%
Debt / Equity-0.06x0.02x0.00x0.01x0.05x0.04x0.00x
FCF Conversion-0.35x0.43x0.35x-0.23x11.99x0.23x-0.00x2.29x
Revenue Growth-31.07%15.68%20.88%-9.41%-13.16%37.33%-18.37%

Revenue by Segment

202220232024
Service-10.41M13.71M
Service Growth--31.77%
Product-9.03M2.15M
Product Growth---76.16%
Total Member14.15M--
Total Member Growth---

Frequently Asked Questions

Growth & Financials

Zhongchao Inc. (ZCMD) reported $30.5M in revenue for fiscal year 2024. This represents a 211% increase from $9.8M in 2017.

Zhongchao Inc. (ZCMD) saw revenue decline by 18.4% over the past year.

Zhongchao Inc. (ZCMD) reported a net loss of $8.2M for fiscal year 2024.

Dividend & Returns

Zhongchao Inc. (ZCMD) has a return on equity (ROE) of -2.8%. Negative ROE indicates the company is unprofitable.

Zhongchao Inc. (ZCMD) had negative free cash flow of $1.6M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.